Bristol-Myers Squibb Co Investor Event to Discuss Data Presented at ASCO Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Gregory B. Gilbert - Truist Securities, Inc., Research Division - Analyst : Can you hear me okay? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.

Question: Gregory B. Gilbert - Truist Securities, Inc., Research Division - Analyst : Great. 2-parter. First, can you speak to your confidence in filing with PFS data? And then secondly, I realize it's somewhat early days for LAG-3 as a mechanism, but do you see the potential for differentiation between LAG-3s that does not seem to exist in the sort of PD-1-versus-PD-1 world? I'm talking about drug versus drug here not driven by a clinical trial strategy.

Question: Gregory B. Gilbert - Truist Securities, Inc., Research Division - Analyst : Just 2 follow-ups. On fixed doses in general, can you talk about where you're drawing the line as a company between combination therapies that should be combined in a fixed dose versus those that should be kept apart? Is that simply technical considerations? Or are there other factors that you're considering because there could be presumably an infinite number of potential fixed-dose combinations as you think out over the years? And my second question is a bit more outside the box, I'd say. Are there cases where a competing PD-1 or PD-L1 has a favorable label versus Opdivo, where it would be unethical for you to conduct a U.S. trial to sort of mimic that part of the label, but where you are considering doing such a study outside the U.S. is the way to sort of normalize labeling over time? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.